Form 4: VolitionRx Secretary's RSU Vesting Boosts Direct Stake

VolitionRx's Secretary, Rodney Gerard Rootsaert, reported the vesting of 28,200 restricted stock units, increasing his direct beneficial ownership of common stock.

Summary

• Rodney Gerard Rootsaert, Secretary of VolitionRx Ltd (VNRX), reported changes in beneficial ownership.
• 28,200 restricted stock units (RSUs) vested on January 22, 2026, out of an initial award of 94,000 RSUs granted on March 17, 2025.
• The vesting was contingent on achieving certain corporate performance goals by June 30, 2025, and December 31, 2025, which were partially met.
• The vested RSUs are subject to a 3-year time-based vesting schedule, with 9,400 units vesting annually on March 17, 2026, 2027, and 2028.
• The remaining 65,800 RSUs from the original award did not vest and were cancelled on June 30, 2025, and January 22, 2026.
• Following this transaction, Mr. Rootsaert directly beneficially owns 165,458 shares of common stock.
• He also indirectly beneficially owns 1,007,718 shares of common stock through Concord International, Inc., where he is a controlling director.

Sentiment

Score: 6

Explanation: The vesting of RSUs is a positive sign of performance goal achievement and insider commitment, but the cancellation of a larger portion of the original award tempers the overall positive sentiment. It's a mixed signal regarding the full achievement of all performance targets.

Positives

• 28,200 restricted stock units (RSUs) vested, indicating that certain corporate performance goals were met.
• Increased direct beneficial ownership by a key officer (Secretary) may signal confidence in the company's future.
• The vesting schedule provides a clear timeline for future share acquisition by the insider.

Negatives

• A significant portion of the original RSU award, 65,800 units, did not vest and were cancelled, suggesting some performance goals were not fully achieved.

Future Outlook

The remaining 28,200 vested restricted stock units are subject to a 3-year time-based vesting schedule, with 9,400 units expected to vest and settle into common stock on March 17, 2026, 2027, and 2028, respectively. This indicates a planned future increase in the reporting person's direct shareholding.

Industry Context

This Form 4 filing details an insider transaction related to executive compensation, which is a routine disclosure for publicly traded companies. It reflects the execution of a pre-existing stock incentive plan for an officer, rather than a broader industry trend or competitive action.

Corporate Governance

Related Party Transactions

• Rodney Gerard Rootsaert indirectly beneficially owns 1,007,718 shares of common stock through Concord International, Inc., where he is a controlling director and shares voting and dispositive control.

Stakeholder Impact

• Shareholders: Increased direct beneficial ownership by a key officer may be viewed positively as it aligns management's interests with shareholders. However, the cancellation of a significant portion of RSUs might raise questions about the full achievement of performance targets.
• Employees: The RSU vesting and cancellation reflect the outcomes of performance-based compensation plans, which can influence employee motivation and perception of company performance.

Next Steps

• Settlement of 9,400 vested RSUs into common stock on March 17, 2026.
• Settlement of 9,400 vested RSUs into common stock on March 17, 2027.
• Settlement of 9,400 vested RSUs into common stock on March 17, 2028.

Key Dates

Keywords

VolitionRx, VNRX, SEC Form 4, insider transaction, beneficial ownership, restricted stock units, RSU vesting, corporate governance, executive compensation, Rodney Gerard Rootsaert, common stock